News | August 12, 2024
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Subscribe To Our Newsletter & Stay Updated
